--- In experimentalandunconventional@yahoogroups.com, altman23
<no_reply@y...> wrote:
> --- In experimentalandunconventional@y..., "Eric Stockel"
> <estockel@m...> wrote:
> > Have you seen any research regarding how a COX-2 inhibitor might
> interact with a patient also on blood thinning medication
(cumidin)?
> My father's onc is reluctant to prescribe celebrex or any other
NSAID
> for fear of internal bleeding.
> >
> > eric
>
>

Platelets Not Disrupted By Celebrex
Results from a double-blind, randomized, placebo-controlled study
published in February's Journal of Clinical Pharmacology revealed
that the mega-popular arthritis drug Celebrex does not interfere
with platelet function even at 1200 mg/day. A dose of 1200 mg/day
is actually 6 times the recommended daily dose of Celebrex
prescribed for the treatment of osteoarthritis. Why is this finding
of maintaining normal platelet function so significant? It is
significant for:

Patients at risk for bleeding
Patients taking medications which increase the risk of bleeding
People with arthritis who take low-dose aspirin for cardiovascular
disease prophylaxis
The purpose of the study was to compare the effects of very high
doses of Celebrex to therapeutic doses of naproxen on platelets.
Participants were randomly given varying doses of Celebrex,
naproxen, or placebo over a 10-day period. Bleeding times were used
to measure platelet function.

In contrast to either Celebrex or placebo, naproxen proved to reduce
platelet aggregation and increase bleeding times. The fact that
Celebrex did not disrupt normal platelet aggregation is more
confirmation of the COX-2 selectivity of the drug and of its safety.

Often osteoarthritis and cardiovascular disease occur together in
elderly people. The CDC (Centers for Disease Control and
Prevention) has estimated that 1 in 4 adults in the United States
has hypertension and up to 1 in 3 people with hypertension also has
arthritis. Approximately 1 in 5 people over 35 years old take
aspirin as a preventative measure against cardiovascular disease.
The study results support Celebrex as a logical choice for people on
the low-dose aspirin regimen.

MORE ON CELEBREX

REFERENCE:
Journal of Clinical Pharmacology, February 16, 2000, MedscapeWire


Cary







> Actually I have - your Dad's onc could be right.
>
> See the package insert for Celebrex
>
> http://www.celebrex.com/u6_important_product_info.asp
>
> Specifically the following:
>
>
*********************************************************************
*
> Warfarin: Anticoagulant activity should be monitored, particularly
> in the first few days, after initiating or changing
> CELEBREX therapy in patients receiving warfarin or similar
> agents, since these patients are at an increased risk of bleeding
> complications. The effect of celecoxib on the anticoagulant
> effect of warfarin was studied in a group of healthy subjects
> receiving daily doses of 2–5 mg of warfarin. In these subjects,
> celecoxib did not alter the anticoagulant effect of warfarin as
> determined by prothrombin time. However, in post-marketing
> experience, bleeding events have been reported, predominantly
> in the elderly, in association with increases in prothrombin
> time in patients receiving CELEBREX concurrently
> with warfarin.
>
*********************************************************************
>
> The doses of Celebrex believed effective for cancer therapy are
very
> high - 800mg/day, so any interaction could be magnified by this
big
> dose. This may be what the onc is thinking of.
>
> I guess different oncs probably have different views regarding the
> risk....which may partly depend on the age/health of the patient
as
> well.